RICHMOND, Va. / Dec 02, 2024 / Business Wire / Owens & Minor, Inc. (NYSE: OMI), announced today that members of its management team are scheduled to participate in two upcoming investor conferences.
Citi 2024 Global Healthcare Conference
On Wednesday, December 4, 2024, Owens & Minor is scheduled to participate in a fireside chat at 8:45 a.m. ET and host individual investor meetings at the conference in Miami, Florida.
Bank of America Home Care Conference
On Monday, December 9, 2024, Owens & Minor is scheduled to participate in a fireside chat at 12:00 p.m. ET and host individual investor meetings at the virtual conference.
About Owens & Minor
Owens & Minor, Inc. (NYSE: OMI) is a Fortune 500 global healthcare solutions company providing essential products and services that support care from the hospital to the home. For over 100 years, Owens & Minor and its affiliated brands, Apria®, Byram® and HALYARD*, have helped to make each day better for the patients, providers, and communities we serve. Powered by more than 20,000 teammates worldwide, Owens & Minor delivers comfort and confidence behind the scenes so healthcare stays at the forefront. Owens & Minor exists because every day, everywhere, Life Takes Care™. For more information about Owens & Minor and our affiliated brands, visit owens-minor.com or follow us on LinkedIn and Instagram.
Last Trade: | US$6.45 |
Daily Change: | -0.43 -6.25 |
Daily Volume: | 1,115,560 |
Market Cap: | US$497.360M |
February 28, 2025 February 11, 2025 February 03, 2025 November 04, 2024 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load